

Haemophilia A Treatment

Reference Number: F4848
Date of Response: 14/09/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. In the last three months, how many patients have been treated by your haemophilia centre with the following products?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

Q2. In the last three months, how many patients were treated with the following products for severe Haemophilia A ONLY?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Obizur
- Refacto AF

The Trust has considered your request. However, to provide you with the information requested under you questions 1 and 2 (above) would require the manual extraction and manipulation of information from various sources .

12. — (1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

The appropriate limit of £450 represents the estimated cost of one person spending two and a half days This would entail Trust staff:-

- Determining whether the information is held.
- Locating the information, or a document containing it.
- Retrieving the information, or a document containing it.
- Extracting the information from a document containing it.

To carry out the above would exceed the appropriate cost limit as set out in Section 12 (1) of the Freedom of Information Act 2000 and is therefore exempt.